Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma

Abstract

Purpose Our aim was to evaluate the prognostic implications of a preoperative novel index, systemic immune inflammation index (SII) in patients undergoing surgery due to renal cell carcinoma. Methods A retrospective analysis of 176 patients who underwent radical nephrectomy and diagnosed with RCC was carried out. Systemic immune inflammation index, which is calculated by neutrophil x platelet/lymphocyte, and other inflammation indexes such as neutrophil/lymphocyte ratio, platelet/lymphocyte were included. The Kaplan-Meier analysis was plotted, and the groups were compared using a log-rank test. The ROC curve for the aforementioned inflammation indexes was plotted. Results SII (× 109/l) for lower and higher T stage group were 743.70 ± 587.55 and 907.06 ± 631.96, respectively, which is statistically significant (p = 0.01). Patients with higher Fuhrman grade (G3 and G4) were found to have higher SII (p = 0.001). SII 830 was demonstrated as the best cutoff value for overall survival. The optimal cutoff point for SII was defined as 850 for disease-specific survival. High SII scores were associated with poor overall survival in RCC patients (p = 0.034). However, no significant association was found for disease-specific survival (p = 0.29). Conclusions Systemic immune inflammation index was found to be associated with increased TNM stage and poor prognosis of RCC patients udergoing radical nephrectomy.

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

“…No available studies were obtained from the Cochrane Library database. A total of 14 studies (11 full-text studies and 3 conference abstracts) were finally included in the present metaanalysis [9,12,13,[14][15][16][17][18][19][20][21][22][23][24]. Figure 1 shows the study selection process.…”

Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

“…The included studies were published from 2016 to 2020, with a sample size between 70 and 646 and a cut-off value of SII between 200 and 1375. Of them, six studies assessed the relationship between SII and prognosis in renal cell carcinoma (RCC) patients, [19,[22][23][24][25][26] two investigated upper tract urothelial carcinoma (UTUC), [20,27] two focused on bladder cancer (BC), [28,29] and three explored PC. [18,30,31] In terms of the research quality evaluation, the NOS score was 9 for three datasets, 8 for six datasets, 7 for one dataset, and 6 for ve datasets, demonstrating that the included articles were overall of high quality.…”

Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis

“…De Giorgi et al suggested that SII appears superior to the NLR as a prognostic marker in mRCC patients treated with immune check-point inhibitors 26 . Furthermore, recently, a retrospective study of 176 RCC patients who underwent radical nephrectomy observed that high SII was associated with poor OS (P=0.034) 27 . SII is also associated with an increased TNM stage, which is similar to our results.…”